In a review article, David A Fruman of the Department of Molecular Biology & Biochemistry, and Institute for Immunology, University of California, Irvine, USA, reviews key challenges and opportunities for the clinical development of inhibitors targeting the PI3K/AKT/mTOR pathway. The authors anticipate that through a greater focus on patient selection, increased understanding of immune modulation and strategic application of rational combinations, it should be possible to realise the potential of this promising class of targeted anti-cancer agents. Read more here.
Study mentioned: Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014 Jan 31;13(2):140-56. PMID: 24481312
No comments:
Post a Comment